Skip to main content

Table 1 Minimum inhibitory concentrations (MIC90, MIC range [mg/L]) and antimicrobial susceptibility (%S) and resistance (%R) of Gram-positive isolates

From: The Tigecycline Evaluation and Surveillance Trial; assessment of the activity of tigecycline and other selected antibiotics against Gram-positive and Gram-negative pathogens from France collected between 2004 and 2016

Organism/ Antimicrobial 2004–2016 2013–2016
MIC90 (mg/L) MIC Range (mg/L) % S % R MIC90 (mg/L) MIC Range (mg/L) % S % R
E. faecalis N = 1429 N = 373
Ampicillina 2 ≤0.06 to ≥32 98.4 1.0 1 ≤0.06 to ≥32 97.1 2.1
Linezolid 2 ≤0.5 to ≥16 99.9 0.1 2 ≤0.5 to ≥16 99.7 0.3
Tigecycline 0.25 ≤0.008 to 0.5 99.9 0.0 0.12 0.03 to 0.25 100 0.0
Vancomycin 2 0.25 to ≥64 99.2 0.8 2 0.25 to ≥64 99.2 0.8
E. faecalis, VRE N = 11 N = 3
Amox-clav ≥16 0.25 to ≥16 81.8 18.2 ≥16 0.5 to ≥16 [1] [2]
Ampicillin ≥32 0.5 to ≥32 81.8 18.2 ≥32 1 to ≥32 [1] [2]
Linezolid 2 1 to ≥16 90.9 9.1 ≥16 1 to ≥16 [2] [1]
Tigecycline 0.25 0.06 to 0.25 100 0.0 0.25 0.06 to 0.25 [3] [0]
E. faecium N = 537 N = 159
Linezolid 2 ≤0.5 to 8 99.8 0.2 2 ≤0.5 to 8 99.4 0.6
Tigecycline 0.25 0.015 to 0.25 100 0.0 0.12 0.015 to 0.25 100 0.0
Vancomycin 2 0.25 to ≥64 94.4 5.6 1 0.25 to ≥64 98.1 1.9
E. faecium, VRE N = 30 N = 3
Linezolid 2 1 to 2 100 0.0 2 1 to 2 [3] [0]
Tigecycline 0.25 0.03 to 0.25 100 0.0 0.25 0.06 to 0.25 [3] [0]
S. aureus N = 3437 N = 947
Levofloxacinb 32 ≤0.06 to ≥64 73.2 26.8 16 ≤0.06 to ≥64 76.7 23.3
Linezolid 2 ≤0.5 to 8 > 99.9 < 0.1 2 ≤0.5 to 8 99.9 0.1
Minocyclineb 0.5 ≤0.25 to ≥16 95.0 3.0 ≤0.25 ≤0.25 to ≥16 97.5 2.1
Penicillin ≥16 ≤0.06 to ≥16 15.0 85.0 ≥16 ≤0.06 to ≥16 16.6 83.4
Tigecycline 0.25 ≤0.008 to 0.5 100 0.0 0.12 0.015 to 0.5 100 0.0
Vancomycin 1 ≤0.12 to 2 100 0.0 1 0.25 to 2 100 0.0
S. aureus, MRSA N = 953 N = 234
Levofloxacinb ≥64 ≤0.06 to ≥64 16.7 83.3 32 0.12 to ≥64 17.5 82.5
Linezolid 2 ≤0.5 to 4 100 0.0 4 ≤0.5 to 4 100 0.0
Minocyclineb 0.5 ≤0.25 to ≥16 94.2 4.6 ≤0.25 ≤0.25 to 8 95.3 3.8
Penicillin ≥16 0.5 to ≥16 0.0 100 ≥16 0.25 to ≥16 0.0 100
Tigecycline 0.25 0.015 to 0.25 100 0.0 0.25 0.015 to 0.5 100 0.0
Vancomycin 1 ≤0.12 to 2 100 0.0 1 0.25 to 2 100 0.0
S. agalactiae N = 1348 N = 378
Levofloxacin 1 ≤0.06 to 32 99.1 0.9 1 0.12 to 32 97.9 2.1
Linezolid 1 ≤0.5 to 2 100 0.0 1 ≤0.5 to 2 100 0.0
Minocycline ≥16 ≤0.25 to ≥16 16.1 82.0 ≥16 ≤0.25 to ≥16 15.6 83.1
Penicillin 0.12 ≤0.06 to 0.12 100 0.0 0.12 ≤0.06 to 0.12 100 0.0
Tigecycline 0.12 0.015 to 4 99.8 0.1 0.12 0.015 to 4 99.7 0.3
Vancomycin 0.5 ≤0.12 to 1 100 0.0 0.5 ≤0.12 to 1 100 0.0
S. pneumoniae N = 1684 (AZM, CLR, CLI, ERY, N = 1500) N = 496 (AZM, CLR, CLI, ERY, N = 473)
Azithromycinb ≥128 ≤0.03 to ≥128 60.5 39.1 ≥128 ≤0.03 to ≥128 65.8 33.8
Ceftriaxone 1 ≤0.03 to 16 80.8 0.5 1 ≤0.03 to 2 84.7 0.0
Clarithromycinb ≥128 ≤0.015 to ≥128 60.9 38.5 ≥128 ≤0.015 to ≥128 66.4 32.6
Clindamycinb ≥128 ≤0.015 to ≥128 68.5 31.5 ≥128 ≤0.015 to ≥128 71.9 28.1
Erythromycinb ≥128 ≤0.015 to ≥128 60.6 38.7 ≥128 ≤0.015 to ≥128 66.4 33.2
Levofloxacin 1 ≤0.06 to ≥64 99.7 0.3 1 ≤0.06 to 2 100 0.0
Linezolid 1 ≤0.5 to 4 99.9 0.0 1 ≤0.5 to 2 100 0.0
Meropenem (N = 1557) c 0.5 ≤0.12 to ≥32 99.8 0.2 1 ≤0.12 to 8 99.8 0.2
Minocyclineb (N = 1683) 8 ≤0.25 to ≥16 52.4 38.6 8 ≤0.25 to ≥16 61.7 31.9
Penicillin 2 ≤0.06 to ≥16 53.0 3.0 2 ≤0.06 to 8 53.4 2.8
Tigecycline 0.06 ≤0.008 to 0.5 0.03 ≤0.008 to 0.06
Vancomycin 0.5 ≤0.12 to 1 100 0.0 0.5 ≤0.12 to 1 100 0.0
S. pneumoniae, PRSP N = 51 (AZM, CLR, CLI, ERY, N = 48) N = 14 (AZM, CLR, CLI, ERY, N = 14)
Azithromycin ≥128 ≤0.03 to ≥128 22.9 77.1 ≥128 0.06 to ≥128 38.5 61.5
Ceftriaxone 2 ≤0.03 to 8 9.8 9.8 2 ≤0.03 to 2 21.4 0
Clarithromycin ≥128 ≤0.015 to ≥128 22.9 77.1 ≥128 ≤0.015 to ≥128 38.5 61.5
Clindamycin ≥128 ≤0.015 to ≥128 37.5 62.5 ≥128 0.03 to ≥128 46.2 53.8
Erythromycin ≥128 ≤0.015 to ≥128 22.9 75.0 ≥128 0.03 to ≥128 38.5 61.5
Levofloxacin 1 0.25 to 16 98.0 2.0 1 0.5 to 1 100 0.0
Linezolid 1 ≤0.5 to 2 100 0.0 1 ≤0.5 to 2 100 0.0
Meropenemc 2 ≤0.12 to ≥32 94.1 5.9 2 ≤0.12 to 8 92.9 7.1
Minocycline ≥16 ≤0.25 to ≥16 19.6 70.6 8 ≤0.25 to ≥16 21.4 64.3
Tigecycline 0.03 0.015 to 0.12 0.03 0.015 to 0.03
Vancomycin 0.5 0.25 to 1 100 0.0 0.5 025 to 1 100 0.0
  1. a indicates statistically significant decrease in susceptibility (p < 0.01) from 2004 to 2016
  2. b indicates statistically significant increase in susceptibility (p < 0.01) from 2004 to 2016
  3. c Meropenem was introduced to the testing panel in 2006, replacing imipenem; N values of activity against organisms collected from 2006 to 2016 are given
  4. Amox-clav, amoxicillin-clavulanic acid, AZM, azithromycin, CLR, clarithromycin, CLI, clindamycin, ERY, erythromycin, MIC, minimum inhibitory concentration, MIC90, minimum inhibitory concentration required to inhibit growth of 90% of isolates (mg/L), MRSA, methicillin-resistant S. aureus, Pip-taz, piperacillin-tazobactam, PRSP, Penicillin-resistant S. pneumoniae, R, resistant, S, susceptible, VRE, vancomycin-resistant enterococci